PTP1B promotes macrophage activation by regulating the NF-κB pathway in alcoholic liver injury.


Journal

Toxicology letters
ISSN: 1879-3169
Titre abrégé: Toxicol Lett
Pays: Netherlands
ID NLM: 7709027

Informations de publication

Date de publication:
01 Feb 2020
Historique:
received: 05 08 2019
revised: 25 10 2019
accepted: 01 11 2019
pubmed: 13 11 2019
medline: 31 12 2019
entrez: 13 11 2019
Statut: ppublish

Résumé

Alcoholic liver injury (ALI) is a part of alcohol-related liver diseases. These diseases include steatohepatitis, alcoholic fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Accumulating data indicates that alcohol metabolism and circulating endotoxin/lipopolysaccharide (LPS) contribute to macrophage activation, which leads to the development of ALI. Protein tyrosine phosphatase 1B (PTP1B) has been shown to be involved in many tissue inflammations as well as liver fibrosis; however, the role of PTP1B in ALI is still unclear. In this study, PTP1B expression was elevated in liver tissues and primary macrophages isolated from EtOH-fed mice. Moreover, PTP1B expression was elevated in RAW264.7 cells stimulated with alcohol and LPS. Additional studies showed that silencing of PTP1B reduced the inflammatory response and expression of inflammatory cytokines such as IL-1β, IL-6 and TNF-α, while overexpression of PTP1B induced inflammation in RAW264.7 cells. In addition, we found that NF-κB pathway was activated in RAW264.7 cells stimulated with alcohol and LPS, and PTP1B silencing or overexpression could regulate NF-κB signaling. In conclusion, this study revealed the function of PTP1B in ALI via its regulation of the NF-κB signaling pathway and may provide theoretical support for further research on ALI.

Identifiants

pubmed: 31711802
pii: S0378-4274(19)30352-2
doi: 10.1016/j.toxlet.2019.11.001
pii:
doi:

Substances chimiques

Central Nervous System Depressants 0
Cytokines 0
Lipopolysaccharides 0
NF-kappa B 0
Ethanol 3K9958V90M
Protein Tyrosine Phosphatase, Non-Receptor Type 1 EC 3.1.3.48
Ptpn1 protein, mouse EC 3.1.3.48

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-21

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Lei Yang (L)

School of Pharmacy, Anhui Medical University, The Key Laboratory of Major Autoimmune Diseases of Anhui Province, Hefei, China; The Key Laboratory of Anti-inflammatory and Immune medicines, Anhui Institute of Innovative Drugs, Hefei, China.

Ying-Yin Sun (YY)

School of Pharmacy, Anhui Medical University, The Key Laboratory of Major Autoimmune Diseases of Anhui Province, Hefei, China; The Key Laboratory of Anti-inflammatory and Immune medicines, Anhui Institute of Innovative Drugs, Hefei, China.

Ya-Ru Liu (YR)

School of Pharmacy, Anhui Medical University, The Key Laboratory of Major Autoimmune Diseases of Anhui Province, Hefei, China; The Key Laboratory of Anti-inflammatory and Immune medicines, Anhui Institute of Innovative Drugs, Hefei, China.

Na-Na Yin (NN)

School of Pharmacy, Anhui Medical University, The Key Laboratory of Major Autoimmune Diseases of Anhui Province, Hefei, China; The Key Laboratory of Anti-inflammatory and Immune medicines, Anhui Institute of Innovative Drugs, Hefei, China.

Fang-Tian Bu (FT)

School of Pharmacy, Anhui Medical University, The Key Laboratory of Major Autoimmune Diseases of Anhui Province, Hefei, China; The Key Laboratory of Anti-inflammatory and Immune medicines, Anhui Institute of Innovative Drugs, Hefei, China.

Hai-Xia Yu (HX)

School of Pharmacy, Anhui Medical University, The Key Laboratory of Major Autoimmune Diseases of Anhui Province, Hefei, China; The Key Laboratory of Anti-inflammatory and Immune medicines, Anhui Institute of Innovative Drugs, Hefei, China.

Xiao-Sa Du (XS)

School of Pharmacy, Anhui Medical University, The Key Laboratory of Major Autoimmune Diseases of Anhui Province, Hefei, China; The Key Laboratory of Anti-inflammatory and Immune medicines, Anhui Institute of Innovative Drugs, Hefei, China.

Jun Li (J)

School of Pharmacy, Anhui Medical University, The Key Laboratory of Major Autoimmune Diseases of Anhui Province, Hefei, China; The Key Laboratory of Anti-inflammatory and Immune medicines, Anhui Institute of Innovative Drugs, Hefei, China. Electronic address: lj@ahmu.edu.cn.

Cheng Huang (C)

School of Pharmacy, Anhui Medical University, The Key Laboratory of Major Autoimmune Diseases of Anhui Province, Hefei, China; The Key Laboratory of Anti-inflammatory and Immune medicines, Anhui Institute of Innovative Drugs, Hefei, China. Electronic address: huangcheng@ahmu.edu.cn.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH